An Imperial-led team has won £1.5M to establish a research network in neuromodulation.
The network, NEUROMOD+: Co-creation for next-generation neuromodulation therapeutics, was funded through the EPSRC and MRC call to build responsible neurotechnology research capability in the UK.
Increasingly, people suffer from debilitating neurological conditions including neurodegenerative diseases and mental health disorders. Neurotechnology is playing an increasingly important part in solving these problems, but the invasiveness of existing approaches limits their overall impact. NEUROMOD+ will represent UK research, industry, clinical and patient communities, working together to address the challenge of minimally invasive treatments for brain disorders.
NEUROMOD+ will bring together neurotechnology stakeholders to co-create next generation, minimally invasive brain stimulation technologies. Simon Schultz NEUROMOD+ lead and Director of Imperial College Centre of Excellence in Neurotechnology
The network will focus on transformative research, new collaborations, and responsible innovation, partnering with bioethicists and policy makers.
NEUROMOD+ will be managed by a consortium of 4 universities, led by Imperial's Centre for Neurotechnology Director Simon Schultz, with co-PIs from Imperial, University of Nottingham, University of Oxford, and University of Edinburgh. The network has initial support from over 50 members across academia, industry, and the healthcare and charity sectors and will launch officially in November 2022, when it will be open to all new members, and host its first co-creation event.
Article text (excluding photos or graphics) © Imperial College London.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
Leave a comment
Your comment may be published, displaying your name as you provide it, unless you request otherwise. Your contact details will never be published.